Global Antiemetics Market to See 6.5% Annual Growth Through 2023

August 09, 2018

WELLESLEY, Mass., Aug 09, 2018–A global increase in the number of pregnancies, expanding use of chemotherapy and radiation, and growing research activity are just a few factors helping boost the global market for antiemetics, according to a report by BCC Research.

The industry expects to see a compound annual growth rate (CAGR) of 6.5% through 2023, when it is expected to top $5.9 billion, according to the report Antiemetics: Technologies and Global Markets.

Major players in the market include Abbott Laboratories, Daiichi Sankyo, Eisai, GlaxoSmithKline, Helsinn Healthcare, IPCA Laboratories, Kyowa Hakko Kirin Pharma, Merck, Novartis, F. Hoffmann-La Roche, Sanofi Aventis and Tesaro.

Research Highlights

  • The 5-HT3 receptor antagonist market accounts for the largest share of the global antiemetic market at 46.5%, followed by NK1 receptor antagonists.
  • By application, antiemetics aimed at chemotherapy-induced nausea and vomiting (CINV) held the largest share of the market at 44.5%, followed by antiemetics for motion sickness and vestibular disorders. The CINV market anticipates a CAGR of 6.5% through 2023.
  • North America dominates the global market with a 36.5% share, though growth will be fastest in the Middle East and Africa, which anticipates a CAGR through 2023 of 6.7%.

“The antiemetic drug market primarily is volume-driven as most of the drugs belonging to this therapeutic class have lost their patent protection and are currently supplied as low-priced generics, affecting the overall growth of the market in terms of value,” the report notes. “The growing numbers of surgical procedures, cancer patients undergoing chemotherapy and radiotherapy, and an increasing number of pregnancies are key the market drivers.”

Market Restraints Include Lack of Animal Models, Pricing Pressure

The prevalence of nausea and vomiting as a side effect to many drugs and treatments means targeting them is a major goal, although both are complex effects to test. The reliance of animal testing, the report notes, has produced inconsistent results, and in recent years major companies in the antiemetic market have issued sweeping drug recalls. An additional negative influence on the market is the widespread use of low-cost generics, which is forcing manufacturers to reduce their own prices to remain competitive. Wholesalers, retailers and reimbursement coordinators are also demanding that drug makers lower their prices.

Editors/reporters requesting analyst interviews should contact Eric Surber at

Antiemetics: Technologies and Global Markets( PHM070B )
Publish Date: Jul 2018    

Data and analysis extracted from this press release must be accompanied by a statement identifying BCC Research LLC as the source and publisher. For media inquiries, email or visit to request access to our library of market research.